Arrowhead Research
ARWR
$70.67
-12.40%
Arrowhead Pharmaceuticals Inc. is a commercial-stage biotechnology company focused on developing RNA interference (RNAi) therapeutics designed to silence genes that trigger diseases associated with genetic abnormalities or protein overproduction. Its pipeline spans cardiometabolic, neuromuscular, pulmonary, and liver diseases, with a platform that targets multiple cell types in the body, positioning it as a differentiated player in the RNAi space alongside larger competitors like Alnylam. The current investor narrative centers on the company's transition from a pure clinical-stage developer to a commercial-stage entity, highlighted by a sharp revenue spike in the March 2025 quarter that drove a rare profit, followed by a return to losses in the subsequent quarter. Recent news flow, including sector momentum from gene-editing peers like CRISPR Therapeutics, has kept attention on the broader genetic medicine space, while Arrowhead's own volatile quarterly results and heavy R&D spending fuel debate over the sustainability of its commercial ramp and pipeline execution.…
ARWR
Arrowhead Research
$70.67
Related headlines
Investment Opinion: Should I buy ARWR Today?
Based on the synthesis of analyst consensus, valuation, and growth prospects, ARWR warrants a Hold rating with a speculative tilt. The core thesis is that the company's pipeline and platform in RNAi therapeutics offer significant long-term potential, but the current valuation already prices in substantial success, and recent financials reveal extreme volatility. The analyst consensus is a strong buy with an average target of $110.00, implying +32.8% upside, but this optimism is tempered by the stock's 178.77% one-year gain and its position at 81.8% of its 52-week range, which limits near-term margin of safety.
Supporting evidence for a Hold includes: (1) the forward PS of roughly 2.26x based on estimated revenue of $2.04 billion, which is attractive if achieved, but the trailing PS of 5.56x and EV/Sales of 17.14x are rich relative to the company's inconsistent profitability; (2) revenue growth is highly volatile, with an 86.41% year-over-year decline in the latest quarter, making it difficult to forecast; (3) profitability is elusive, with a net margin of -0.20% and negative ROE of -0.35%; (4) free cash flow is negative at -$50.87 million on a trailing basis, and the company relies on equity issuance; and (5) the implied upside to the analyst average target is +32.8%, but the downside risk to the 52-week low is -66%. The risk/reward is balanced but skewed by the high valuation and execution risk.
The biggest risks that could invalidate the thesis are: (1) a failure to convert pipeline candidates into commercial revenue, leading to a cash crunch and further dilution; (2) increased competition from larger RNAi players like Alnylam, which could erode market share; and (3) a high beta of 1.284, which amplifies downside in a market downturn. The rating would upgrade to Buy if the company demonstrates two consecutive quarters of sustainable revenue growth above $150 million and positive free cash flow, or if the stock pulls back to the $60–$70 range, improving the risk/reward. It would downgrade to Sell if revenue fails to materialize, cash burn accelerates, or the stock breaks below $70 on high volume. Relative to its own history, the PS ratio is near the low end of its range (5.56x vs. a high of 938.86x), but on an absolute basis, the valuation appears full, leaving little room for error.
Sign up to view all
ARWR 12-Month Price Forecast
The forward-looking view on ARWR is cautiously neutral, balancing the strong analyst consensus and pipeline potential against significant execution and financial risks. The bull case (25% probability) hinges on successful pipeline readouts and partnership deals driving revenue toward $2 billion, while the base case (55%) assumes moderate growth and range-bound trading. The bear case (20%) reflects the risk of clinical or commercial failure, which could send the stock back to the $50–$70 range or lower. The key factors are the company's ability to convert its RNAi platform into sustainable revenue, manage its cash burn, and compete with larger players. I would upgrade to bullish if ARWR reports two consecutive quarters of revenue above $150 million with positive free cash flow, and downgrade to bearish if revenue fails to exceed $100 million in any quarter or if a major pipeline candidate fails.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Arrowhead Research's 12-month outlook, with a consensus price target around $110.00 and implied upside of +55.6% versus the current price.
Average Target
$110.00
0 analysts
Implied Upside
+55.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$100 - $126
Analyst target range
Arrowhead is covered by 12 analysts, with a consensus recommendation of "strong buy" and a recommendation mean of 1.31 (where 1 is a strong buy and 5 is a strong sell). The average target price is $110.00, which implies an upside of approximately +32.8% from the current price of $82.85. The bullish consensus is reinforced by recent institutional actions, including Morgan Stanley's upgrade to Overweight from Equal Weight in April 2026 and repeated Buy ratings from HC Wainwright and B. Riley Securities. This suggests that the analyst community remains confident in the company's pipeline and commercial prospects despite recent quarterly losses.
The target price range spans from a low of $100.00 to a high of $126.00, a relatively tight spread of 26% around the average, indicating strong conviction among analysts. The high target of $126.00 likely assumes successful pipeline readouts, accelerated partnership revenue, and multiple expansion, while the low target of $100.00 still represents a +20.7% upside and may price in slower commercial adoption or higher R&D costs. The estimated EPS average of $4.41 for the forward year, with a range of $1.99 to $9.14, highlights significant uncertainty in profitability forecasts, but the skew toward positive earnings supports the bullish narrative. Overall, the analyst data points to a high-conviction bullish stance, with limited downside expected from current levels.
Bulls vs Bears: ARWR Investment Factors
The bull case for ARWR rests on a powerful technical uptrend (+178.77% 1-year), a unanimous strong buy analyst consensus with a $110 average target (+32.8% upside), and expectations of a significant forward revenue inflection to $2.04 billion. However, the bear case is equally compelling: revenue collapsed 86.41% year-over-year in the latest quarter, net income swung to a $132.73 million loss, and the company continues to burn cash with negative trailing free cash flow of -$50.87 million. The most critical tension is whether the March 2025 revenue spike was an anomaly or the start of a sustainable commercial ramp — if forward revenue fails to materialize, the current valuation (5.56x trailing PS, 17.14x EV/Sales) could compress sharply. Currently, the bear evidence on fundamentals is stronger, but the bull momentum and analyst conviction provide a powerful counterweight. The resolution of this debate hinges on pipeline execution and the timing of additional partnership revenue.
Bullish
- Analyst consensus strong buy with 32.8% upside: All 12 covering analysts rate ARWR a strong buy (recommendation mean 1.31), with an average target price of $110.00 versus the current $82.85, implying +32.8% upside. The target range is tight ($100–$126), signaling high conviction and limited disagreement among analysts.
- Massive relative strength and momentum: ARWR has surged +178.77% over the past year, crushing the S&P 500's +16.22% and delivering +162.55% relative strength. The stock trades at 81.8% of its 52-week range ($28.12–$95.49), confirming a powerful primary uptrend.
- Forward revenue inflection expected: Analysts estimate average forward revenue of $2.04 billion, which would imply a forward PS of roughly 2.26x based on the $4.61 billion market cap — a sharp compression from the trailing PS of 5.56x. This suggests the market expects a major commercial ramp or additional partnership milestones.
- Strong liquidity and manageable leverage: The current ratio of 4.86 and debt-to-equity of 0.79 indicate solid short-term liquidity and reasonable leverage for a commercial-stage biotech. The company also generated positive free cash flow of $81.88 million in the latest quarter, aided by $795.72 million in net financing.
Bearish
- Revenue collapse and earnings volatility: Q2 2026 revenue plunged 86.41% year-over-year to $73.74 million, down from $542.71 million in the prior-year quarter, which was inflated by a one-time collaboration payment. Net income swung from a $370.45 million profit to a $132.73 million loss, highlighting extreme earnings instability.
- Heavy cash burn and negative free cash flow: Trailing twelve-month free cash flow is -$50.87 million, and R&D expenses remain elevated at $173.25 million in the latest quarter. The company relies on equity issuance ($221.65 million in the latest quarter) to fund operations, diluting shareholders.
- Rich valuation on weak fundamentals: The trailing PS of 5.56x and EV/Sales of 17.14x are elevated for a company with inconsistent profitability and a net margin of -0.20%. The price-to-book ratio of 9.90x further suggests the market is pricing in optimistic pipeline outcomes with little margin for error.
- Negative profitability metrics: The company reported a negative ROE of -0.35% and ROA of -8.10%, indicating that capital is not being deployed profitably. The operating margin in the latest quarter was -191.57%, and the cash flow coverage ratio of 0.06 is weak, raising concerns about debt servicing from operations.
ARWR Technical Analysis
Arrowhead is in a powerful, sustained uptrend, with a 1-year price change of +178.77% dwarfing the S&P 500's +16.22% over the same period. At a current price of $82.85, the stock sits at approximately 81.8% of its 52-week range (low of $28.12, high of $95.49), meaning it is trading in the upper echelon of its annual band but not at the extreme high. This positioning signals strong momentum and market confidence, though it also implies limited margin of safety for new entrants and vulnerability to profit-taking near the highs. The 6-month gain of +50.50% and year-to-date rise of +22.22% further confirm the bullish primary trend, with the stock having more than doubled from its 52-week low.
Short-term momentum has cooled noticeably, with a 1-month decline of -5.04% contrasting sharply with the +11.18% gain over 3 months and the +178.77% 1-year surge. This divergence suggests a temporary pullback or consolidation phase within a larger uptrend, rather than a trend reversal, especially given the stock's relative strength of +162.55% versus the S&P 500 over 1 year. The 1-month relative strength of -3.98% indicates underperformance against the market recently, which could be a mean-reversion pause after an extended run. Volume of 1,335,809 shares is moderate, and with a short ratio of 8.12, there is potential for short-covering to amplify any renewed upward move, though it also reflects persistent bearish bets.
Key technical support lies near the 52-week low of $28.12, but more immediate support is likely around the $70-$75 zone, which coincides with the July 2026 consolidation area. Resistance is defined by the 52-week high of $95.49; a breakout above this level would signal a continuation of the primary uptrend and could attract momentum buyers, while a breakdown below $70 would suggest a deeper correction. The stock's beta of 1.284 means it is approximately 28.4% more volatile than the broader market, implying that position sizing should account for amplified moves in both directions. The maximum drawdown of -24.64% over the observed period underscores the potential for sharp reversals, reinforcing the need for disciplined risk management.
Beta
1.28
1.28x market volatility
Max Drawdown
-24.6%
Largest decline past year
52-Week Range
$28-$95
Price range past year
Annual Return
+146.5%
Cumulative gain past year
| Period | ARWR Return | S&P 500 |
|---|---|---|
| 1m | -18.4% | -2.4% |
| 3m | -12.8% | +2.2% |
| 6m | +24.1% | +14.8% |
| 1y | +146.5% | +14.6% |
| ytd | +4.2% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ARWR Fundamental Analysis
Arrowhead's revenue trajectory is highly volatile and event-driven, typical of a commercial-stage biotech with lumpy licensing and milestone payments. The most recent quarter (Q2 2026, ended March 31, 2026) reported revenue of $73.74 million, a decline of 86.41% year-over-year from the $542.71 million recorded in the prior-year quarter, which had been inflated by a large one-time collaboration payment. Sequentially, revenue fell from $264.03 million in Q1 2026 and $256.47 million in Q4 2025, indicating that the March 2025 spike was an anomaly rather than a sustainable run-rate. This erratic top-line performance makes it difficult to assess underlying commercial momentum, though the company's pipeline progress and partnership deals remain the primary growth drivers.
Profitability is equally uneven, with net income swinging from a profit of $370.45 million in the March 2025 quarter to a loss of $132.73 million in the March 2026 quarter, a dramatic reversal. The gross margin is reported at 100% in quarters with revenue, reflecting the absence of cost of goods sold for licensing revenue, but this metric is not meaningful for assessing operational efficiency. Operating margin in the latest quarter was -191.57%, and R&D expenses remained elevated at $173.25 million, underscoring the heavy investment required to advance the pipeline. The company's net margin of -0.20% on a trailing basis highlights that it is barely breakeven at best, and the path to sustained profitability depends on successful commercialization and additional partnership revenue.
On the balance sheet, Arrowhead shows a current ratio of 4.86 and a debt-to-equity ratio of 0.79, indicating reasonable liquidity but a growing debt load. Free cash flow over the trailing twelve months was -$50.87 million, reflecting ongoing cash burn, though the most recent quarter generated positive free cash flow of $81.88 million due to working capital swings and a $663.46 million debt repayment that was offset by $795.72 million in net financing. Cash at the end of the March 2026 quarter was $188.52 million, down from $201.64 million the prior quarter, and the company has relied on common stock issuance ($221.65 million in the latest quarter) to fund operations. The negative ROE of -0.35% and ROA of -8.10% signal that capital is not yet being deployed profitably, and the cash flow coverage ratio of 0.06 is weak, suggesting limited ability to service debt from operations alone.
Quarterly Revenue
$73737000.0B
2026-03
Revenue YoY Growth
-86.4%
YoY Comparison
Gross Margin
100.0%
Latest Quarter
Free Cash Flow
$-50872000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ARWR Overvalued?
Because Arrowhead's trailing net income is negative (EPS of -$0.00035), the PE ratio is not meaningful, and the trailing PE of -2827.05 confirms this. Therefore, the PS ratio is the appropriate primary metric, currently at 5.56x trailing sales. The forward PE of -17.24 is also negative, reflecting expected losses, but the forward PS can be inferred from estimated revenue of $2.04 billion, which would imply a forward PS of roughly 2.26x based on the current market cap of $4.61 billion. The gap between trailing and forward PS suggests the market expects a significant revenue acceleration, likely driven by pipeline milestones or commercial launches.
Compared to the biotechnology industry, where price-to-sales ratios for commercial-stage companies often range from 3x to 8x depending on growth, Arrowhead's trailing PS of 5.56x is within the mid-to-upper range. However, its EV/Sales of 17.14x is notably elevated, reflecting the company's debt and cash position, and the EV/EBITDA of 28.84x is high for a company with inconsistent profitability. The price-to-book ratio of 9.90x is also rich, suggesting the market is assigning substantial value to intangible pipeline assets. Without a clear peer average from the provided data, it is difficult to quantify the premium, but the multiples imply that investors are pricing in robust future growth that has yet to materialize in consistent financial results.
Historically, Arrowhead's PS ratio has been extremely volatile, ranging from a low of 3.13x in March 2025 (when revenue spiked) to a high of 938.86x in December 2024 (when revenue was near zero). The current 5.56x is near the lower end of this historical band, which could indicate a value opportunity if revenue normalizes at a higher level, or it could reflect skepticism about the sustainability of recent revenue. The price-to-book ratio of 9.90x is below the 14.54x seen in March 2026 but above the 4.21x in June 2025, suggesting the stock is not cheap on an asset basis. Overall, the valuation appears to be pricing in optimistic pipeline outcomes, leaving little room for execution missteps.
PE
-2827.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
28.8x
Enterprise Value Multiple
Investment Risk Disclosure
Arrowhead faces significant financial and operational risks stemming from its erratic revenue and persistent cash burn. The company's revenue is highly event-driven, as evidenced by the 86.41% year-over-year decline in Q2 2026 to $73.74 million following a one-time collaboration payment in the prior-year quarter. Net income swung from a $370.45 million profit to a $132.73 million loss, and trailing free cash flow is -$50.87 million, forcing reliance on equity issuance ($221.65 million in the latest quarter) that dilutes shareholders. With R&D expenses at $173.25 million and a cash balance of $188.52 million, the company has limited runway without additional financing or partnership revenue, and its negative ROE (-0.35%) and ROA (-8.10%) indicate capital is not yet being deployed profitably.
Market and competitive risks are amplified by ARWR's high beta of 1.284, meaning it is approximately 28.4% more volatile than the broader market. The stock trades at a premium valuation, with a trailing PS of 5.56x and an EV/Sales of 17.14x, leaving it vulnerable to multiple compression if growth expectations are not met. Competition in the RNAi space is intense, with larger players like Alnylam potentially overshadowing Arrowhead's commercial efforts. Additionally, sector rotation risk is real: recent news highlights momentum in gene editing (CRISPR Therapeutics), which could draw investor attention away from RNAi-focused companies. The recent 1-month decline of -5.04% and relative underperformance of -3.98% versus the S&P 500 suggest that momentum may be waning.
The worst-case scenario for ARWR would involve a failure of its pipeline to deliver commercial results, leading to a revenue shortfall and a cash crunch. If the company's forward revenue estimates of $2.04 billion prove overly optimistic, the stock could retest its 52-week low of $28.12, representing a -66% decline from the current price of $82.85. Even a moderate correction to the analyst low target of $100 would be a +20.7% gain, but that assumes pipeline success. A more realistic bear case might see the stock fall to the $50–$60 range, a -28% to -40% decline, if revenue remains lumpy and cash burn continues. The maximum drawdown of -24.64% over the observed period underscores the potential for sharp reversals, and with a short ratio of 8.12, a negative catalyst could trigger a cascade of selling.
FAQ
The key risks for ARWR are ranked as follows: (1) Financial risk: revenue is highly volatile, with an 86.41% year-over-year decline in the latest quarter, and trailing free cash flow is -$50.87 million, forcing reliance on equity issuance and diluting shareholders. (2) Execution risk: the company's pipeline is unproven commercially, and any clinical trial failure or partnership delay could devastate the stock. (3) Competitive risk: larger players like Alnylam dominate the RNAi space, and Arrowhead may struggle to gain market share. (4) Macro risk: with a beta of 1.284, the stock is 28.4% more volatile than the market, and a sector rotation away from biotech could amplify losses. The most severe risk is a cash crunch if revenue does not materialize, which could send the stock below $50.
The 12-month forecast for ARWR includes three scenarios: bull case (25% probability) with a target range of $110–$126, driven by successful pipeline readouts and partnership deals; base case (55% probability) with a target range of $95–$110, assuming moderate revenue growth and stable R&D spending; and bear case (20% probability) with a target range of $50–$70, reflecting pipeline failures or commercial disappointments. The base case is most likely, hinging on the assumption that revenue grows to approximately $1.8 billion and the company avoids major setbacks. The analyst average target of $110 aligns with the base case, implying +32.8% upside from the current price.
ARWR appears overvalued on trailing metrics but could be fairly valued if forward estimates are met. The trailing PS of 5.56x and EV/Sales of 17.14x are elevated for a company with inconsistent profitability and a net margin of -0.20%. However, the forward PS of roughly 2.26x, based on estimated revenue of $2.04 billion, suggests the market expects a significant revenue inflection. The price-to-book ratio of 9.90x is also rich, indicating that intangible pipeline assets are a major component of the valuation. Compared to its own history, the current PS is near the low end of its range (5.56x vs. a high of 938.86x), but on an absolute basis, the stock is not cheap. The market is pricing in successful pipeline execution and commercial ramp, leaving little margin for error.
ARWR presents a high-risk, high-reward opportunity that may be suitable for aggressive investors, but it is not a conservative buy. The analyst consensus is a strong buy with a $110 average target, implying +32.8% upside from the current $82.85, and the stock has surged +178.77% over the past year. However, the company reported a net loss of $132.73 million in the latest quarter, with revenue down 86.41% year-over-year, and it continues to burn cash with negative trailing free cash flow of -$50.87 million. The valuation is rich, with a trailing PS of 5.56x and EV/Sales of 17.14x, leaving little room for error. For investors with a high risk tolerance and a long-term horizon, a small position could be justified, but only if they can withstand a potential -66% drawdown to the 52-week low of $28.12.
ARWR is more suitable for long-term investment by risk-tolerant investors, given its early commercial stage, high volatility (beta 1.284), and lack of dividends. The company's growth potential in RNAi therapeutics could reward patient shareholders over a 3–5 year horizon, but short-term trading is highly risky due to event-driven revenue and earnings volatility. The stock's 1-month decline of -5.04% and maximum drawdown of -24.64% illustrate the potential for sharp reversals. A minimum holding period of at least 2–3 years is recommended to allow pipeline catalysts to materialize. Short-term traders might capitalize on momentum, but they must employ strict risk management given the stock's 28.4% higher volatility than the market.